CARDIAC AND HEPATIC DYSFUNCTION IN HYPERTENSIVE PATIENTS BY ASSOCIATION OF LIVER FIBROSIS INDICES 4 AND 5

Maria Cristina Tatar,Marta German-sallo,Dan Petrisor Runcan
DOI: https://doi.org/10.1097/01.hjh.0001021352.53401.73
IF: 4.9
2024-05-01
Journal of Hypertension
Abstract:Objective: To study heart failure in close relation with left ventricular ejection fraction, NT-proBNP, as well as hepatic impairment by calculating liver fibrosis index (FIB-4 and FIB-5) in hypertensive patients admitted to our internal medicine clinic. Design and method: We studied 500 patients diagnosed with heart failure (HF), admitted to our internal medicine clinic between 2022-2023 with a mean age of 72.12 years. We selected 460 patients previously diagnosed with hypertension out of 500 (92% with hypertension) of which 46.09% were female and 53.91% male. Left ventricular ejection fraction (LVEF) was analysed by echocardiographic determination in different types of HF. Liver function was assessed based on the formulas of FIB-4 [Age (year) × AST (IU/l)]/[platelet count (× 109/l) × ALT (IU/l)1/2] and FIB-5 [albumin (g/l) × 0. 3 + platelet count (109/l) × 0.05 - alkaline phosphatase (IU/l) × 0.014 + AST/ALT ratio × 6 + 14], and data were taken from inpatient analyses. Correlations between FIB-4, FIB-5 and LVEF, respectively NT-proBNP were analysed using Spearman's nonparametric test. A p-value less than 0.05 was considered statistically significant. Results: The mean value of FIB-4 parameter was 1.80 ±0.42 while the mean of FIB-5 parameter was -11.6 ± 5.61. EF had a mean value in the whole studied group patients of 42.9 ± 2 towards 10.2. A significant correlation was demonstrated between LVEF in patients included in the entire group and the parameters FIB-4 (p=0.0008, 95% CI) and FIB-5 (p=0.0098, 95% CI). The same results were observed in patients previously diagnosed with hypertension regarding LVEF and FIB-4 (p=0.0016) as well as FIB-5 (p=0.0276). No significant correlation (p>0.05) was found between the mean value of NT-proBNP (5890.94 pg/mL) and FIB-4/FIB-5 indices in patients with HF regardless the presence of hypertension. Conclusions: In HF patients previously diagnosed with hypertension, decreasing EF will result in a significant increase in liver fibrosis risk, but we didn’t observed the same trend regarding the biomarkers for HF. Further research is needed in order to analyse the link between LVEF, NT-proBNP and liver fibrosis indices
peripheral vascular disease
What problem does this paper attempt to address?